BESREMi® (ropeginterferon alfa-2b-njft) Injection Is Available From Onco360!
BESREMi® is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera.
Dosage and Administration1
- Recommended starting dose: 100 mcg by subcutaneous injection every 2 weeks (50 mcg if receiving hydroxyurea).
- Increase the dose by 50 mcg every 2 weeks (up to a maximum of 500 mcg) until hematological parameters are stabilized
- Interrupt or discontinue dosing if certain adverse reactions occur
Dosage Forms and Strengths
Injection: 500 mcg/mL solution in a single-dose prefilled syringe (NDC 73536-500-01)
For full prescribing information, visit Besremi.com
1BESREMi® Prescribing Information: PharmaEssentia Corporation accessed 11/2021. BESREMi® is a trademark/registered trademark of PharmaEssentia © 2021 PharmaEssentia